[A case of bromocriptine-induced interstitial pneumonitis in an iron factory worker exposed to sand dust].
A 62-year-old male, was admitted on Oct. 7, 1987 because of productive cough and dyspnea. He worked for an iron factory, where pneumoconiosis was regarded as an occupational disease, for 40 years. No abnormal finding had been noted on his mass screening chest roentgenograms. He was well until three years ago when hypertension and Parkinsonism were noted. Since then he was treated with beta blockers, L-DOPA, amantadine and bromocriptine. Two weeks before admission, he suddenly complained of dyspnea and productive cough. His chest roentgenograms showed diffuse reticulonodular infiltration in both lung fields. The partial pressure of oxygen of the arterial blood was 65.9 Torr. The first transbronchial lung biopsy obtained from right B8 on Sept. 29, 1987 (before the admission) revealed some epithelioid granulomas and the second biopsy obtained from right B10 on Oct. 14, 1987 demonstrated bronchiolar edema and infiltration of inflammatory cells. Fibrotic changes associated with carbon dust between airways and vessels were also noted. Lymphocyte stimulation index by bromocriptine was 362%, and that by amantadine, 139%, L-DOPA, 150%, respectively. After ceasing the administration of bromocriptine, productive cough, dyspnea and the reticulonodular shadows diminished gradually. These findings strongly suggest that the interstitial pulmonary lesions are bromocriptine-induced interstitial pneumonitis. His occupational exposure to inorganic dust may be a predisposing factor.
Itoh
H
H
Watanabe
A
A
Ooka
T
T
Kitagawa
M
M
D001971:Bromocriptine / Q000009:adverse effects*; D004391:Dust / Q000009:adverse effects*; D004781:Environmental Exposure; D006801:Humans; D007501:Iron; D008297:Male; D008669:Metallurgy; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced*
D004391:Dust; D001971:Bromocriptine; D007501:Iron